Anemia remains one of the most impactful complications of chronic kidney disease, affecting quality of life, cardiovascular risk, and overall outcomes. The 2026 updates from Kidney Disease: Improving Global Outcomes (KDIGO) bring important changes to screening thresholds, iron therapy strategies, use of erythropoiesis-stimulating agents, and emerging treatments.

This session will break down the key recommendations from the latest KDIGO guidance into practical steps for clinicians managing CKD patients. Expect a clear review of when to investigate anemia, how to individualize iron and ESA therapy, safety considerations, and integrating new evidence into real-world practice—helping clinicians deliver safer, more effective anemia care in CKD.